Mara Monetti, Director of PIL and Director of the Proteomics Core, comes to MSK from Pfizer, where she created a mass spectrometry-based proteomics center to provide expertise and state-of-the-art instrumentation for the advancement of scientific programs across all research groups at Pfizer’s Kendall Square research site. Dr. Monetti brings a wealth of knowledge about the latest technologies and advances in proteomics and she is inspired t contributing to MSK’s core mission. Dr. Monetti obtained her PhD in experimental pharmacology from the University of Milan in Italy and did postdoctoral work on proteomics with Matthias Mann at the Max Plank Institute of Biochemistry in Munich.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Mara Monetti discloses the following relationships and financial interests:
-
Pfizer, Inc.
Equity
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
View all disclosures